

***Fiscal Year 2023 Department of Defense Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCR-CTA</p>	<p>Independent investigators at all academic levels.</p>	<p>Supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer.</p> <ul style="list-style-type: none"> • Proposed projects may range from small, proof-of-concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1, or 1/2). • Preliminary data are required. Larger, more-definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 26, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>
<p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCR-CTRA</p>	<p>The Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent).</p>	<p>Supports correlative studies that address translational research in high-impact or unmet needs in ovarian cancer and have a clinical emphasis.</p> <ul style="list-style-type: none"> • Applications focused on the following OCRP priority are encouraged: <ul style="list-style-type: none"> – Utilize precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes. • Clinical trials are not allowed. • 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 26, 2023 5:00 p.m. ET</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent).</p> <p>Partnering PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.</p>	<p>Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.</p> <ul style="list-style-type: none"> • Clinical trials are not allowed. • If cell lines or animals are used, justification for use is required. • Research aimed at extending the lives of advanced state and recurrent patients is encouraged. • Preliminary data are required. • <i>Pre-application is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is: • \$600,000 for direct costs for a single PI. • \$800,000 for direct costs for Partnering PIs • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): April 17, 2023 5:00 p.m. ET</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>
<p>Ovarian Cancer - Clinical Trial Academy Leadership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCRP-OCCTA-LA</p>	<p>The Clinical Trial Academy Leadership team should have strong expertise in ovarian cancer research. At least one member of the leadership team must be an established, board-certified oncologist with experience in in therapeutic or non-therapeutic clinical trials.</p> <ul style="list-style-type: none"> • A joint application of the Dean and Assistant Dean is required. 	<p>Leadership team consists of an academy dean and assistant dean. Supports building an interactive academy led by visionary individuals who are established ovarian cancer researchers. This academy will focus on developing investigators interested in developing clinical trials on ovarian cancer in a collaborative research and career development environment.</p> <ul style="list-style-type: none"> • A clinical researcher, translational researcher, and Mentor should be included in the academy structure. • The Academy Dean and the Assistant Dean are responsible for facilitating regular interactive communication among all Academy members. • Proof of principle is requested. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): May 26, 2023 5:00 p.m. ET</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Ovarian Cancer Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCRP-OCA-ECI</p>	<p>Investigators must be within 5 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.</p>	<p>Supports the addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations, and a peer group for junior faculty.</p> <ul style="list-style-type: none"> • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required. • A Designated Mentor may only mentor one ECI. • The Designated Mentor is not required to be at the same institution as the ECI. • Preliminary data are required. • Clinical trials are allowed. • <i>Pre-application is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): April 17, 2023 5:00 p.m. ET</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>
<p>Pilot Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-OCRP-PA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).</p>	<p>Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.</p> <ul style="list-style-type: none"> • Innovation is an important review criterion. • The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed. • Clinical trials are not allowed. • Research aimed at extending the lives of advanced-state and recurrent patients is encouraged. • <i>Pre-application is required and blinded; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): April 17, 2023 5:00 p.m. ET</p> <p>Application: July 21, 2023 11:59 p.m. ET</p>